Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But according to a new Canadian study, adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.